%0 Journal Article
%T Atezolizumab: state of art and future perspective in non-small cell lung cancer treatment
%A Federico Cappuzzo
%A Lorenza Landi
%A Silvia Vecchiarelli
%J SCIE-indexed Journal
%D 2018
%R 10.21037/20960
%X Lung cancer is the first cause of cancer deaths worldwide (1). Nowadays, treatment landscape of non-small cell lung cancer (NSCLC) is rapidly changing by the introduction of immune-checkpoint inhibitors (2,3). Programmed death-1 (PD-1), a key immune-checkpoint receptor expressed by activated T cells, down-regulates immune responses through binding to its ligand, programmed death ligand-1 (PD-L1). PD-L1 is expressed by tumor cells (TCs), tumor-infiltrating immune cells (ICs), or both (4). The US Food and Drug Administration (FDA) approved three immune-checkpoint inhibitors, the two anti-PD-1 nivolumab and pembrolizumab and the anti-PD-L1 atezolizumab, with substantial improvement in the management of NSCLC, both in first- (5) and second-line setting (2,3,6-8)
%U http://tcr.amegroups.com/article/view/20960/html